143 results
Page 5 of 8
PRE 14A
01ss6j4
17 Apr 20
Preliminary proxy
4:18pm
8-K
EX-99.1
y2d65f3
13 Apr 20
ENDRA Life Sciences Announces Cash Strategy and Business Update in Response to COVID-19
4:29pm
8-K
EX-1.1
yxx5e
27 Mar 20
Entry into a Material Definitive Agreement
5:19pm
424B5
sg004w33
27 Mar 20
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
a4q5w s28
26 Mar 20
ENDRA Life Sciences Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
4:07pm
8-K
EX-99.1
r9rc d0lb
10 Mar 20
ENDRA Life Sciences Receives CE Mark for its TAEUS® Clinical Product Targeting Non-Alcoholic Fatty Liver Disease
8:02am
424B3
424ec1u vghwpe05
28 Jan 20
Prospectus supplement
4:59pm
8-K
EX-99.1
d0q7hql
15 Jan 20
ENDRA Life Sciences Renews GE Healthcare Collaboration Agreement
10:12am
8-K
EX-10.1
zfc76eb0gd1 dk0tl
26 Dec 19
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-4.2
orskxv98wj lwe3
26 Dec 19
Entry into a Material Definitive Agreement
4:15pm
D
fm4897u30ta6
20 Dec 19
$8.56M in equity / debt / securities to be acquired, sold $8.56M, 151 investors
4:06pm
8-K
EX-4.2
n0hc 711coqagajc
11 Dec 19
ENDRA Life Sciences Completes $8.1 Million Private Placement
5:14pm
8-K
EX-10.1
3a14 4c1dz61uzblasi
11 Dec 19
ENDRA Life Sciences Completes $8.1 Million Private Placement
5:14pm
8-K
EX-99.1
b5tb689latm p5
11 Dec 19
ENDRA Life Sciences Completes $8.1 Million Private Placement
5:14pm
8-K
EX-99.1
8cu 5f29d
13 Nov 19
ENDRA Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results
4:05pm